Navigation Links
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
Date:12/17/2010

of marketing authorization approval from the European Commission for the use of pirfenidone for the treatment of IPF and the expected timing thereof, statements regarding commercial launch preparations and statements regarding the various anticipated durations of patent protection and marketing exclusivity.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, (i) whether the European Commission approves the marketing authorization for pirfenidone for the treatment of IPF and the actual timing of the decision; (ii) risks related to unexpected regulatory actions or delays or government regulation generally; (iii) risks related to the clinical and regulatory process for pirfenidone, including having no unexpected safety, toxicology, clinical or other issues; (iv) unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; (v) government, industry and general public pricing pressures; (vi) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections; (vii) risks related to building the infrastructure required for commercial launch in various countries in the European Union, and (viii) those other factors discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 15, 2010 (the "Form 10-K"), and other periodic reports filed with the SEC.  The risks and other factors discussed above should be considered only
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune to Release Third Quarter Financial Results on October 28
2. InterMune Sells Danoprevir Rights to Roche for $175 Million
3. InterMune to Present at 2010 Citi Health Care Conference
4. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
5. InterMune to Release First Quarter Financial Results on April 29
6. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
7. InterMune Announces Proposed Public Offering of Common Stock
8. InterMune to Release Third Quarter Financial Results on November 5
9. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
10. InterMune to Present at Canaccord Adams Conference
11. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 The ... such as its definition, classification, application and ... specification, manufacturing process, and product cost structure. ... applications. The analysis also covers upstream raw ... industry development trend and proposals. In the ...
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... Inc., the leader in room temperature sample storage and ... Robb to the Scientific Advisory Board. ... with over 45 years experience in the fields of ... a Governor of the College of American Pathologists, an ...
... - May 25, 2011 - Semiconductor Research,Corporation ... and related technologies, and researchers from the,UCLA ... Science have,developed a new method of design-dependent ... promises to provide,semiconductor chip manufacturing cost and ...
... 11 earthquake and rolling blackouts that are severely affecting ... program NanoJapan is scrambling to run its annual summer ... to Japan for lab internships, NanoJapan is offering partner ... to Rice University laboratories for three months. "This ...
Cached Biology Technology:Biomatrica Announces the Appointment of Dr. James A. Robb as a Member of the Scientific Advisory Board 2Biomatrica Announces the Appointment of Dr. James A. Robb as a Member of the Scientific Advisory Board 3SRC and UCLA advance design-dependent process monitoring for semiconductor wafer manufacturing 2Reverse NanoJapan: Rice to host 25-30 Japanese students 2
(Date:12/22/2014)... Conn. , Dec. 22, 2014  NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... pickpocket, entertainer and security consultant, Apollo Robbins ... biometric smart wallet.  Apollo Robbins ... and 7 th , 2015, demonstrating some of his ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... free throws don't quite turn out the same way each time, ... mostly in your head. That's the finding of new research published ... engineers at Stanford University. , "The main reason you can't move ... golf club, is that your brain can't plan the swing the ...
... first known laboratory studies that explores memory deficits associated ... Mayo Clinic researchers have evidence that this infection can ... which was conducted in animal models, suggests that over ... possibly have a permanent effect on memory late in ...
... scientists have identified a cell population that is a ... frontotemporal dementia, which is as common as Alzheimer's disease ... , Because the cells arose only recently in evolutionary ... and humans-- and are particularly abundant in humans, and ...
Cached Biology News:On the golf tee or pitcher's mound, brain dooms motion to inconsistency 2On the golf tee or pitcher's mound, brain dooms motion to inconsistency 3Mayo Clinic study suggests that a central nervous system viral infection can lead to memory deficits 2Mayo Clinic study suggests that a central nervous system viral infection can lead to memory deficits 3Study offers window into human behavior, brain disease 2Study offers window into human behavior, brain disease 3Study offers window into human behavior, brain disease 4
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
... Mouse Antibody to Human Cytokeratin TYPE II ... (Type II) keratins. Including epidermal cell keratin ... 58kD, 65kD and 67kD. Broad keratin reactivity ... and cornea. Immunogen: ...
... System is intended for use in the ... an in-house validated method for in vitro ... of interest. • ... hybridization capture assay designed to detect amplified ...
... culture scale-up, these culture chambers produce cell ... 9 range and are useful alternatives ... • High mechanical • strength and structural ... shipping • Certified nonpyrogenic and sterilized by ...
Biology Products: